Report Overview

2023

Base Year

2018-2023

Historical Year

2024-2032

Forecast Year

Diabetic Macular Edema Market Regional Analysis

Geographically, the United States is expected to lead throughout the forecast period, owing to the presence of a robust healthcare system and major market players. The continuous research activities in the region also contribute to the market growth. There has been significant emphasis on leveraging gene therapy to allow access to improved solutions. In November 2023, scientists deployed gene therapy ABBV-RGX-314 to allow controlled release of dexamethasone in patients with diabetic macular edema and retinal vein occlusion. Developed by collaborative efforts of RegenXBio and AbbVie, ABBV-RGX-314 is a monoclonal antibody fragment, administered through an injection. When tested in a cohort of 100 patients with DME, it reduced vision threatening events by 89% and prevented disease progression as well. Hence, it can be used as a potential treatment in the future.

Europe, with its robust healthcare infrastructure and significant portion of geriatric population has high diabetic macular edema market demand. Consequently, the existence of prominent academic and research institutions aids market size, with continuous developments and activities to develop effective solutions for the patients in the region.

Diabetic Macular Edema Market Report Snapshots

Diabetic Macular Edema Market Size

Diabetic Macular Edema Market Regional Analysis

Diabetic Macular Edema Treatment Companies

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market attained a value of about USD 6.7 billion in 2023 driven by increasing incidence of diabetes across the 8 major markets.

The market is anticipated to grow at a CAGR of 5.1% during the forecast period of 2024-2032 and is likely to reach a market value of USD 10.4 billion by 2032.


The increasing research and development activities to discover a cure for condition, integration of technical advancements and prevalence for minimally invasive treatments are fuelling the market demand. 
 

The surge in FDA approvals to facilitate improved solutions to the patients is a major market trend. In August 2023, FDA approved Regeneron’s EYLEA HD (aflibercept) Injection 8 mg for treating diabetic macular edema and related eye conditions. The approval was based on the results of 48-week PULSAR and PHOTON trials, wherein the drug candidate helped in significant vision gains in patients.

Based on disease type, the market is divided into focal diabetic macular edema and diffuse diabetic macular edema.

Hospitals fluorescein angiography, fundus imaging, and optical coherence tomography (OCT) among others are common diagnostic methods.

The route of administration can include intravitreal injections and implants.

The major regions of the market include the United States, EU-4, the United Kingdom, Japan and India.

Various types of treatments include oral iron therapy, parenteral iron therapy, and red blood cell transfusion.

Major distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others.

End users in the market are hospitals, clinics, and home healthcare, among others.

Key players involved in the market are LEO Pharma, Amneal Pharmaceuticals, AstraZeneca, Johnson & Johnson Private Limited, Bausch Health Companies Inc., Eli Lilly and Company, AbbVie Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., and Abbott.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,499

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,699

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,599

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,599

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

$getforecastarray = array(); if (isset($ismapshow)) { $forecast_period_start = isset($forecast_period_start) ? $forecast_period_start : ''; if ($forecast_period_start != "") { $yearInc = 1; for ($startfrom = $forecast_period_start; $startfrom <= $forecast_period_end; $startfrom++) { $calculatFercastYear=calculateFutureValue(($getReportDetail['base_value']> 0) ? $getReportDetail['base_value'] : 100, $getReportDetail['cagr'], $yearInc); $getforecastarray[] = array('years' => "$startfrom", 'value' => $calculatFercastYear); $yearInc++; } } } $getforecastarrayJson = json_encode($getforecastarray); ?>